Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.

@article{Schmid2015AssessmentOA,
  title={Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.},
  author={Sabine P Schmid and Aurelius Gabriel Omlin and David M. Blum and Florian Strasser and Silke Gillessen and C Rothermundt},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2015},
  volume={26 11},
  pages={2221-47}
}
BACKGROUND In the past years, there has been significant progress in anticancer drug development for patients with metastatic castration-resistant prostate cancer (CRPC). However, the current instruments to assess clinical treatment response have limitations and may not sufficiently reflect patient benefit. Our objective was to systematically identify tools to evaluate both patient benefit and clinical anticancer-treatment response as basis for an international consensus process and development… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 13 times. VIEW TWEETS

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…